BPC-157 Research Guide: Human Evidence, Safety & FDA Status

Evidence-graded BPC-157 guide covering human studies, animal research, current clinical trials, formulation limits, FDA compounding concerns, and 2026 anti-doping status.

BPC-157 is an investigational 15-amino-acid peptide studied extensively in cells and animals. Those experiments include gastrointestinal injury, tendon and ligament healing, vascular signaling, and organ-injury models. They do not establish that BPC-157 heals injuries or treats disease in people.

The human evidence remains small and uncontrolled. No BPC-157 product is FDA-approved, no administration route has a validated clinical dosing regimen, and FDA's 2026 review proposed against adding BPC-157 free base or acetate to the 503A Bulks List. This page separates those facts from preclinical findings and marketing claims.

Evidence Snapshot

Question	Current answer
Is BPC-157 FDA-approved?	No. FDA reports no approved product containing BPC-157 free base or acetate in any country.
Does it heal tendon, ligament, muscle, or gut injury in humans?	Unknown. Animal findings are broad, but controlled human efficacy evidence is absent.
Has it been given to humans?	Yes, in a few small reports and meeting abstracts. The studied routes and populations differ substantially.
Is there an established human dose?	No. Published and registered studies do not create a generally validated regimen.
Is long-term safety known?	No. Human samples are small, follow-up is short, and product quality is not standardized.
Is it prohibited in tested sport?	Yes. The 2026 World Anti-Doping Agency list names BPC-157 under S0, non-approved substances.

What BPC-157 Is

FDA describes BPC-157 free base as a pentadecapeptide fragment with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. The agency distinguishes the free base from its acetate salt because they are different bulk drug substances, even though they share the same active peptide moiety.

Property	BPC-157 free base	BPC-157 acetate
Active peptide	BPC-157	BPC-157
CAS number	137525-51-0	216441-37-1
Reported molecular formula	C62H98N16O22	Free base plus acetate counter-ion
Reported free-base molecular weight	1,419.5 g/mol	Depends on salt composition
FDA approval	None	None

These identifiers come from the FDA's July 2026 BPC-157 briefing document. FDA also noted inconsistent naming, incomplete characterization, and confusion between free-base and acetate material in submitted certificates of analysis. A label that says only “BPC-157” therefore does not establish which bulk substance or impurity profile is present.

What about arginate, “stable” BPC-157, and blends?

Commercial names such as “BPC-157 arginate” or “stable BPC-157” do not identify an FDA-approved formulation or a clinically validated category. The same is true for blends with TB-500, GHK-Cu, or other peptides. There are no controlled human trials showing that these combinations are synergistic, safer, or more effective than either component alone.

Human Evidence

FDA's 2026 review identified five small clinical studies or meeting abstracts. Each used a different route or clinical question, and none provides the kind of replicated, randomized evidence needed to establish routine treatment efficacy.

Knee pain: uncontrolled retrospective series

A 2021 retrospective report identified 17 people who received an intra-articular injection; 16 were reached by telephone and 12 had received BPC-157 without the TB4 combination. Eleven of those 12 reported meaningful pain improvement. The study had no placebo group, mixed several causes of knee pain, used no standardized functional outcome, and relied on variable retrospective follow-up. It can generate a hypothesis, but it cannot distinguish a treatment effect from placebo response, natural recovery, co-interventions, or selection bias. Lee and Padgett, 2021 (PMID 34324435)

Interstitial cystitis: 12-person single-arm pilot

A 2024 report described 12 women with interstitial cystitis who received intravesical BPC-157 injections. The absence of randomization, a control group, blinding, and a large safety sample makes both efficacy and safety conclusions preliminary. Lee et al., 2024 (PMID 39325560)

Intravenous safety: two previously exposed participants

A 2025 pilot infused 10 mg and then 20 mg in two adults who had already received intravenous BPC-157 before entering the study. Selected laboratory values and vital signs did not show a short-term signal, and the participants reported no adverse effects. With only two previously exposed people and several days of observation, the study cannot characterize uncommon, delayed, immune-mediated, or long-term risks. It did not test efficacy. Lee and Burgess, 2025 (PMID 40131143)

Rectal-enema studies: limited abstract-level reporting

FDA summarized one short study in 24 healthy participants and an exploratory ulcerative-colitis study of approximately 26 participants. The available information is largely limited to meeting abstracts, with incomplete methods, outcome reporting, and safety monitoring. FDA concluded that the available data do not support BPC-157 as a treatment for ulcerative colitis.

Current Registered Trials

ClinicalTrials.gov currently returns three intervention records involving BPC-157. Registration shows that research was planned or conducted; it does not prove benefit.

Trial	Current registry status	What it can eventually answer
NCT07437547	Recruiting; phase 2; estimated 120 participants	Whether a 14-day subcutaneous regimen changes recovery after acute hamstring strain compared with placebo
NCT07752381	Completed; 40 participants; no results posted	Effects of a BPC-157-containing gummy on exercise-recovery markers
NCT02637284	Status unknown; estimated 42 participants; no results posted	Oral safety and pharmacokinetics in healthy volunteers

The registry was checked on August 29, 2026. Until results are posted and independently assessed, none of these records establishes clinical efficacy or a general dosing standard.

What the Preclinical Research Shows

The strongest BPC-157 literature is preclinical. It supports biological plausibility and identifies questions for human trials, but animal doses, injury models, and routes cannot be converted directly into personal treatment instructions.

Gastrointestinal injury models

Early studies reported reduced gastric and duodenal lesions in rats exposed to stress, cysteamine, ethanol, or other experimental injury conditions. These are induced animal lesions, not clinical trials in people with ulcer disease or inflammatory bowel disease. Sikirić et al., 1994 (PMID 7904712)

Tendon and ligament models

In rat Achilles-tendon and cell/explant experiments, BPC-157 was associated with tendon outgrowth, cell survival under oxidative stress, migration, and phosphorylation of FAK and paxillin. That work suggests a possible cell-migration pathway; it does not prove repaired human tendons or establish a human regimen. Chang et al., 2011 (PMID 21030672)

Separate rat experiments reported improved structural or functional measures after Achilles-tendon or medial-collateral-ligament transection. Both are surgical animal models. Starešinić et al., 2003 (PMID 14554208) and Cerovečki et al., 2010 (PMID 20225319)

Proposed mechanisms

Frequently discussed mechanisms include vascular signaling, nitric-oxide-system interactions, cell migration, cytoprotection, and growth-factor-related signaling. These mechanisms come from cells and animal models, often from a limited number of collaborating research groups. No single molecular target has been validated as the mechanism of a demonstrated clinical benefit in humans.

Routes and Dosing: What Is Actually Known

Route	Human evidence boundary
Oral	One old phase 1 registry record with unknown status and no posted results; one completed gummy study with no posted results
Subcutaneous	A recruiting placebo-controlled hamstring trial; no efficacy results yet
Intra-articular	One small uncontrolled retrospective knee-pain series
Intravesical	One 12-person uncontrolled interstitial-cystitis pilot
Intravenous	One two-person short-term safety pilot
Rectal	Short exploratory studies reported mainly as meeting abstracts
Intramuscular, nasal, sublingual, topical	No reliable controlled human efficacy evidence identified

This route diversity should not be read as a menu of interchangeable options. Absorption, sterility requirements, tissue exposure, immunogenicity, degradation, and impurity risks differ by formulation and route. There is no evidence-based conversion between animal doses, clinic protocols, and consumer products.

Safety and Product-Quality Limits

“No serious adverse events reported” in a few small studies does not mean “proven safe.” Small samples are poorly equipped to detect uncommon events, delayed immune reactions, interactions, contamination, or harms from repeated exposure.

FDA's review identified several unresolved issues:

insufficient clinical information to characterize short- or long-term safety;
no formal human immunogenicity studies;
potential aggregation and peptide-related impurities, especially for injectable and nasal formulations;
incomplete characterization of identity, purity, microbial quality, endotoxins, and other critical quality attributes;
FAERS reports including injection-site reaction, shortness of breath, and pigmentation changes, although causality could not be determined.

FDA currently lists BPC-157 among bulk substances that may present significant safety risks in compounding. The agency's 2026 scientific review proposed that neither free base nor acetate be added to the 503A Bulks List. Advisory-committee discussion and a proposal are not themselves an approval or a final determination.

Regulatory and Sports Status

United States: BPC-157 is not FDA-approved. Compounded drugs are not FDA-approved products, and FDA does not review their safety, effectiveness, or quality before marketing.
International approval: FDA's 2026 review reported no approved BPC-157 free-base or acetate product in any country.
Tested sport: The 2026 WADA Prohibited List explicitly includes BPC-157 in class S0, prohibited at all times.

How to Read a New BPC-157 Claim

Before treating a headline, clinic page, or product description as evidence, ask:

Was the study conducted in people, animals, isolated cells, or tissue explants?
Was there randomization, blinding, a control group, and a prespecified outcome?
Was the exact free base, acetate salt, formulation, and route characterized?
Were results peer-reviewed and fully published, or only registered or presented as an abstract?
Was safety monitored long enough and in enough participants to detect more than immediate common effects?
Has an independent group replicated the finding?

That framework prevents a mechanistic result—such as increased cell migration—from being rewritten as a human healing claim.

Bottom Line

BPC-157 has a substantial preclinical literature and a very small human literature. The appropriate conclusion is not that the peptide “does nothing,” nor that animal results establish a treatment. It is that clinical efficacy, validated dosing, product consistency, and long-term safety remain unresolved while better-controlled trials are beginning or awaiting results.